ライフサイエンスコーパス: P

1 P-Rex1 has also become increasingly recognized for its r

2 P-tau217 did not change in amyloid-beta-negative partici

3 P. gingivalis (ATCC 33277) was grown in broth culture, a

4 = .048), and 59.2% (95% CI, 49.4% to 69.0%; P = .08), respectively, in NWTS-5.

5 (IQR: 1.0-1.6) vs 4.6 mmol/L (IQR: 2.8-8.0), P < 0.01], and fraction of inspired oxygen [25% (IQR: 21

6 bution hazard ratio, 9.0; 95% CI, 1.50-54.0; P = .02) was independently associated with post-HCT AIC.

7 similar between groups (O:E = 0.65 vs 1.00, P = 0.11 and O:E = 0.79 vs 1.00, P = 0.15, respectively)

8 65 vs 1.00, P = 0.11 and O:E = 0.79 vs 1.00, P = 0.15, respectively).

9 15.5%; adjusted HR=0.85 [95% CI, 0.72-1.00], P=0.05).

10 ent (61/92 [66%] vs 84% [391/465] P < 0.001, P for interaction by regimen 0.49).

11 nted fixation; HR, 0.95 [95% CI, 0.90-1.01]; P = .08).

12 score (beta: -0.119; 95% CI: -0.208, -0.029; P = 0.009).

13 logy and survivor psychological QOL (B=0.03, P<0.05) and moderated the association between care partn

14 (B=0.05, P<0.001) and psychological (B=0.04, P<0.001) QOL.

15 3; P = .012 vs ADH1B*1: OR, 0.96; P = .048) (P < .01 for the difference in the effect of moderate alc

16 symptoms and care partner physical (B=0.05, P<0.001) and psychological (B=0.04, P<0.001) QOL.

17 g: rho = -0.31, P = 0.30; Older: rho = 0.06, P = 0.86).

18 fference, -0.37% [95% CI, -0.66% to -0.08%]; P = .01).

19 iated with 90% lower odds (odds ratio, 0.09; P = .005) of A/H1N1 illness.

20 to month 3 in all 3 groups by 1.4% to 2.1% (P < 0.001), and %HEX increased by a statistically signif

21 ll 3 sets of blood cultures (15.4% vs 45.1%; P = .005) and had less severe clinical presentations (me

22 arly/mild ILA at enrollment (63.3% vs. 6.1%; P < 0.0001).Conclusions: Rare and common environmental e

23 , forced vital capacity (P = .0017), FEV(1) (P = .037), and total lung capacity (P = .013) but not th

24 = 74) had lower post-bronchodilator FEV(1) (P = 0.007), FEV(1)/FVC (P = 0.003), and greater computed

25 SPs were solitary (69.0%; 95% CI, 45.9-92.1; P = .08), with diameters of 10 mm or more (19.3%; 95% CI

26 iated with Crohn's development (100% vs 11%; P < 0.01) compared with mild or nonspecific inflammation

27 entage than GTR after 3 (P = 0.026) and 120 (P = 0.038) months.

28 ual energy intake (beta: 16.052, R2 = 0.123; P = 0.001).

29 and increased epithelial cell density (13%; P < 0.001).

30 peaked on day 7 and declined toward day 14 (P = .004).

31 eye at presentation (mean, 20/62 vs. 20/149; P < 0.001) and postoperative month 6 (mean, 20/41 vs. 20

32 h AF was more significant (odds ratio, 6.15, P=3.26x10(-14)) when restricting to LOF variants located

33 t (pooled SMD -0.31 [95% CI -0.45 to -0.16], P < 0.001, I = 44.3, N = 1398).

34 143 died (4%) vs 362 of 2095 patients (17%, P < .001).

35 old lower during the follow-up year (n = 18, P = .03).

36 [95% confidence interval {CI}, 1.27-29.18], P = .02) and with positive cervical methylation (aOR, 6.

37 on in GCF was associated with GDM (RR: 1.19; P = 0.045; CI 95% 1.00 to 1.40; and RR: 1.20; P = 0.063;

38 0.001) in Study 1 and with time in Study 2 (P < 0.001).

39 vivors treated with 0 < CED < 4,000 mg/m(2) (P = 3.1 x 10(-4)) and 24 male survivors treated with CED

40 of 10 mm or more (19.3%; 95% CI, 12.4-26.2; P = .13) and were proximal (71.5%; 95% CI, 63.5-79.5; P

41 l carcinomatosis (RR: 5.9; 95% CI: 3.8, 9.2; P = .03).

42 = 0.045; CI 95% 1.00 to 1.40; and RR: 1.20; P = 0.063; CI 95% 0.99 to 1.45 in the adjusted model).

43 nted fixation; HR, 0.94 [95% CI, 0.73-1.21]; P = .61) and overall mortality (cumulative incidence at

44 e ad libitum meal (beta: 17.612, R2 = 0.213; P < 0.001) and the habitual energy intake (beta: 16.052,

45 .9%; hazard ratio, 1.60 [95% CI, 1.15-2.22]; P=0.005).

46 mortality (HR: 8.027; 95% CI: 2.387-18.223; P = 0.026) and optimal cut-off value was 1039 (AUC: 0.80

47 sed treatment (60% [12/20] vs 86% [214/248], P = 0.002) and for those on DTG-based treatment (61/92 [

48 90; 95% confidence interval [CI], 1.60-2.25; P = 5.88 x 10(-13)).

49 The submitted variant set included 28 P/LP variants, 96 VUS, and 34 LB/B variants, mostly in c

50 in genetics (aOR, 2.89; 95% CI, 1.95, 4.29, P = .001), and genetics self-efficacy (aOR, 2.38; 95% CI

51 the mean IOP was 12.6 +/- 4.4 mmHg (n = 29, P = 0.519) on 2.0 +/- 1.6 (P = 0.457) glaucoma medicatio

52 e root coverage percentage than GTR after 3 (P = 0.026) and 120 (P = 0.038) months.

53 6% (15.4%-19.8%) versus 18.9% (15.4%-22.3%) (P = 0.54) and between 2012 and 2017, 17.2% (14.7%-19.7%)

54 seous metastases (RR: 1.9; 95% CI: 1.6, 2.3; P = .02); RB1 mutation (seen in 19 of 103 patients, 18.4

55 piratory failure (OR, 4.7; 95% CI, 1.1-26.3; P = 0.049).

56 mmHg (95% confidence interval [CI], 1.4-7.3; P = 0.005) and mean increase in IOP outside office hours

57 , P = 0.001), and GRS score >0.597 (HR 2.30, P = 0.04) were independent predictors of de novo HCC.

58 nts]; hazard ratio, 0.93 [CI, 0.67 to 1.30]; P = 0.67).

59 ORD-BP, ORIGIN, and TRIUMPH, total N = 3059, P = 0.005).

60 eductions in MCAv(mean) (Young: rho = -0.31, P = 0.30; Older: rho = 0.06, P = 0.86).

61 areer development award funding (55% vs 33%, P = 0.03) and more publications [median 70 (interquartil

62 < 0.001), increased mucosal thickness (34%; P < 0.001), and increased epithelial cell density (13%;

63 ce of means, -7.13 [95% CI, -14.59 to 0.34]; P=0.0611).

64 betes (HR 2.39, P = 0.01), albumin (HR 0.35, P = 0.001), and GRS score >0.597 (HR 2.30, P = 0.04) wer

65 methylation (aOR, 6.49 [95% CI, 1.66-25.35], P = .007), but not significantly higher in women with po

66 , but final VA was similar (20/36 vs. 20/37; P = 0.68).

67 pg/mL: 3285 (1697-6179) vs 1290 (758-3719); P < 0.001 and in patients developing CPC vs no-CPC (area

68 cess measure (0.22 SD; 95% CI, 0.05 to 0.38; P = 0.03), but this could not be attributed conclusively

69 tio [HR] 2.54, P = 0.02), diabetes (HR 2.39, P = 0.01), albumin (HR 0.35, P = 0.001), and GRS score >

70 n, day 2: 40.9% +/- 9.7% vs. 59.2% +/- 4.4%, P < 0.001).

71 4%; P = .26), 57.5% (95% CI, 47.6% to 67.4%; P = .048), and 59.2% (95% CI, 49.4% to 69.0%; P = .08),

72 compared with 57.5% (95% CI, 47.6% to 67.4%; P = .26), 57.5% (95% CI, 47.6% to 67.4%; P = .048), and

73 2.0; 95% confidence interval (CI), 1.2-3.4, P = 0.009), coronary artery disease (OR, 1.9; 95% CI, 1.

74 1.7; 95% confidence interval [CI]: 1.2, 2.4; P = .002) and osseous metastases (RR: 1.9; 95% CI: 1.6,

75 survival (adjHR, 2.04; 95% CI, 1.22 to 3.40; P < .01).

76 vs. SLT, 19.0%; RR, 1.37; 95% CI, 1.33-1.42; P < 0.001).

77 y associated with Braak stage (|rho| > 0.45, P < 0.01) and Thal phase (rho > 0.55, P < 0.01), respect

78 62% lower mortality risk (aHR: 0.310.380.46, P < 0.001) beyond this.

79 ased treatment (61/92 [66%] vs 84% [391/465] P < 0.001, P for interaction by regimen 0.49).

80 iated with NMO, led by rs9272219 (OR = 2.48, P = 8 x 10(-10)).

81 e and a mean +0.26-g/dL (95% CI: 0.04, 0.48; P = 0.02) increase in hemoglobin but no effect on anthro

82 ostoperative month 6 (mean, 20/41 vs. 20/49; P = 0.03), but final VA was similar (20/36 vs. 20/37; P

83 l group, 11.8 metabolic equivalents +/- 5.5; P < .0001).

84 and were proximal (71.5%; 95% CI, 63.5-79.5; P = .008).

85 ntly higher than in the SOC arm (34%, 18/53; P < .001; relative risk [RR] 2.48, 95% CI 1.54-3.95), an

86 range): 5196 (1823-9061) vs 1934 (831-5301); P = 0.005].

87 Male sex (hazard ratio [HR] 2.54, P = 0.02), diabetes (HR 2.39, P = 0.01), albumin (HR 0.3

88 0.45, P < 0.01) and Thal phase (rho > 0.55, P < 0.01), respectively.

89 ment-emergent nephrotoxicity in 10% and 56% (P = .002), respectively.

90 was greater vitreous echodensity (R: 0.573; P < .01) and degradation in CSF (R: 0.611; P < .01).

91 d in African Americans from ACCORD (N = 585, P = 0.02) and in external cohorts (ACCORD-BP, ORIGIN, an

92 changes, including increased branching (59%; P < 0.001), increased mucosal thickness (34%; P < 0.001)

93 4.4 mmHg (n = 29, P = 0.519) on 2.0 +/- 1.6 (P = 0.457) glaucoma medications.

94 2% (14.7%-19.7%) versus 23.2% (19.8%-26.6%) (P = 0.005).

95 r 10 or more years, 1.5 (95% CI, 1.4 to 1.6, P < .001).

96 roup difference (95% CI): 1.89 (0.18, 3.60); P = 0.03; eta2p = 0.29] and skeletal muscle uptake of gl

97 5; 95% confidence interval [CI], 1.18, 2.60, P = .01), AA identity (aOR, 1.67; 95% CI, 1.02, 2.72, P

98 range [IQR], 17-41] vs. 60 min [IQR, 45-60], P = 0.002).

99 or ER and esophagectomy were 53% versus 61% (P = 0.3), respectively.

100 ; P < .01) and degradation in CSF (R: 0.611; P < .01).

101 ard ratio [HR], 3.05 [95% CI, 1.65 to 5.62]; P < 0.001).

102 ut PVTT undergoing upfront LDLT (5-y OS 65%, P = 0.06; RFS 66%, P = 0.33, respectively).

103 (RR Q4 versus Q1 = 2.40; 95% CI: 1.24, 4.65; P-trend = 0.003) and a score of sphingomyelins with full

104 upfront LDLT (5-y OS 65%, P = 0.06; RFS 66%, P = 0.33, respectively).

105 artile range, IQR 55-100) vs 40 (IQR 22-67), P = 0.03].

106 elf-efficacy (aOR, 2.38; 95% CI, 1.54, 3.67, P = .001) were positively associated with ApoL1 test int

107 (RR Q4 versus Q1 = 3.15; 95% CI: 1.75, 5.67; P-trend <0.001) both were positively associated with ris

108 by a statistically significant amount (0.7%, P = 0.030) in the timolol group.

109 months (95% confidence interval 20.3-45.7), P = 0.03].

110 ry artery disease (OR, 1.9; 95% CI, 1.1-3.7; P = 0.04), and respiratory failure (OR, 4.7; 95% CI, 1.1

111 office hours of 2.7 mmHg (95% CI, 0.61-4.7; P = 0.013) than the lowest quintile, which were signific

112 ompared to those without PDR (85% [605/713], P < 0.001), and for those on EFV-based treatment (60% [1

113 AA identity (aOR, 1.67; 95% CI, 1.02, 2.72, P = .04), perceived kidney disease risk following donati

114 ing donation (aOR, 1.68; 95% CI, 1.03, 2.73, P = .03), interest in genetics (aOR, 2.89; 95% CI, 1.95,

115 g characteristic-area under the curve: 0.77; P = 0.001).

116 he cumulative patient measures (rho = 0.781; P < .001).

117 pathological regression (TRG1-2 = 44% vs 8%, P < 0.001) and a trend to tumor downstaging as compared

118 mpared with the 3-lead system (0% versus 8%; P=0.03).

119 ed with an 11.0% point (95% CI: -18.1, -3.8; P < 0.01) adjusted relative reduction in anemia prevalen

120 xygen [25% (IQR: 21-31) vs 42% (IQR: 30-80), P < 0.01] differed between survivors and non-survivors.

121 ed risk of definite NASH (ADH1B*2: OR, 0.80; P < .01 vs ADH1B*1: OR, 0.96; P = .036) and a reduced ri

122 optimal cut-off value was 1039 (AUC: 0.801; P = 0.002).

123 the model (likelihood-ratio statistic: 2.81, P = 0.094), providing an accurate prediction for almost

124 relative to baseline, >=10%; accuracy, 82%; P = 0.004).

125 = 0.032) and HIF1alpha expression (R = 0.83, P = 0.043).

126 ity score of 4 or higher (ADH1B*2: OR, 0.83; P = .012 vs ADH1B*1: OR, 0.96; P = .048) (P < .01 for th

127 (R = 0.903, P = 0.005) and MCT 1 (R = 0.85, P = 0.032) and HIF1alpha expression (R = 0.83, P = 0.043

128 (adjusted hazard ratio [aHR]: 2.493.494.89, P < 0.001), but a 62% lower mortality risk (aHR: 0.310.3

129 PSA; 95% confidence interval [CI], 0.8, 0.9; P < .001).

130 tly correlated with tumor volume (R = 0.903, P = 0.005) and MCT 1 (R = 0.85, P = 0.032) and HIF1alpha

131 survival (adjHR, 1.83; 95% CI, 1.15 to 2.92; P < .01) and overall survival (adjHR, 2.04; 95% CI, 1.22

132 showed 28% reduced risk (95% CI: 0.54, 0.93; P for trend: 0.031) of BC compared with the lowest intak

133 rrelated in donor plasma units (rho = 0.938; P < .001) and in the cumulative patient measures (rho =

134 B*2: OR, 0.80; P < .01 vs ADH1B*1: OR, 0.96; P = .036) and a reduced risk of an NAFLD activity score

135 *2: OR, 0.83; P = .012 vs ADH1B*1: OR, 0.96; P = .048) (P < .01 for the difference in the effect of m

136 mg/L (IQR: 83-179) vs 73 mg/L (IQR: 12-98), P < 0.01), lactate [1.1 mmol/L (IQR: 1.0-1.6) vs 4.6 mmo

137 multivariable HR of 0.84 (95% CI, 0.70-0.99; P trend = 0.04) for the proximal colon cancer incidence.

138 ciated with severe asthma exacerbations at a P value of .01 or less in the same direction of associat

139 ere within +/-10 ppm (mass error) and with a P-Score <=1 x 10(-04).

140 42% of the variation in MTXPG accumulation (P = 1.1 x 10-38).

141 naptic plasticity in this mouse model of AD (P = 0.007 to untreated APP/PS1).

142 hly ranibizumab treatments were younger age (P < 0.0001) and worse baseline BCVA (P < 0.0001).

143 etes or obesity when compared to no-CCY (all P > 0.05), but were less likely to have a previous C-sec

144 A, and those with lower CD4 cell counts (all P < .05).

145 d higher short- and long-term mortality (all P < 0.05).

146 ts with PXS and normal control subjects (all P < .001) without a difference between PXS and control e

147 significantly outperformed using DCE alone (P < 0.001).

148 icant predictors of psoas area (P = .014 and P < .0001, respectively).

149 fective than TIV in preventing all-cause and P&I hospitalization from NHs during an A/H3N2 predominan

150 to simultaneous reductions in mycelial N and P contents.

151 The anion [P(4)O(11)](2-), employed as its bis(triphenylphosphine)i

152 d with the number of courses of antibiotics (P-value > 0.05), but it was significantly associated wit

153 d were significant predictors of psoas area (P = .014 and P < .0001, respectively).

154 We found 41 loci associated (P < 5 x 10(-8)) with left-handedness and 7 associated wi

155 Twenty associations P(FDR) < 0.05 were detected between lipidomic features a

156 positive transcription elongation factor b (P-TEFb), composed of CDK9 and cyclin T, stimulates trans

157 er age (P < 0.0001) and worse baseline BCVA (P < 0.0001).

158 However, testing this is challenging because P varies within landscapes as a function of geology, top

159 Steric shielding due to the bulky P-substituent gives marked different reactivities at the

160 the isomer (C(6)H(4), O)(C, N, Ph) formed by P-stereomutation involving a M(B2) permutational mechani

161 fferent carrot cultivars when parasitized by P. aegyptiaca.

162 outer membrane perturbation can be sensed by P. aeruginosa to activate the T6SS even when the disrupt

163 ass B1 NDM-1 and VIM-2 MBLs, and the class C P. aeruginosa AmpC.

164 eir lung carbon monoxide diffusion capacity (P = .12).

165 FEV(1) (P = .037), and total lung capacity (P = .013) but not their lung carbon monoxide diffusion c

166 n scores (P < .0001), forced vital capacity (P = .0017), FEV(1) (P = .037), and total lung capacity (

167 ow-severity cases (0.98 vs 0.40 events/case, P < 0.001).

168 x 10-9; BMPR1B/UNC5C, P = 9.7 x 10-9; CDH10, P = 1.2 x 10-8) and one locus that was significantly ass

169 vely, compared to those in the other cities (P = 0.001).

170 P = 2.1 x 10-3), and MTX systemic clearance (P = 4.4 x 10-2) explained 42% of the variation in MTXPG

171 We used a diverse set of 58 complete P. aeruginosa genomes to curate a set of 4,440 core gene

172 may inspire novel approaches for controlling P. aeruginosa infections.

173 a significantly higher WCC(P=0.014) and CRP(P=0.004) on admission in P2.

174 ng to a submicron gradient of activated CtrA-P(19) that is stable and sublinear.

175 - and 16-g/d dosages (compared with 0-8 g/d, P < 0.05) and blood urea nitrogen increased with dosage

176 phrin-B1 in astrocytes during postnatal day (P) 14-28 period would affect synapse formation and matur

177 the gene encoding butyryl-coA dehydrogenase (P=0.02).

178 ease onset, were collated to produce a DELTA-P score for each patient.

179 were comparable to those for three different P. jirovecii qPCR assays.

180 d during drying was significantly different (P < 0.001) when comparing sound tooth surfaces, lesion a

181 eal evidence of a significant discontinuity (P=0.66).

182 d blood urea nitrogen increased with dosage (P = 0.013) and time (P < 0.001) in Study 1 and with time

183 ificant after adjusting for career duration (P = .083, .459, and .113, respectively).

184 actors that regulate stimulation-dependent E-P interactions.

185 hat inhibitory phosphorylation of eIF2alpha (P-eIF2alpha), a conserved translation initiation factor,

186 greater computed tomography-based emphysema (P = 0.02) compared with 1,411 white individuals without

187 Performance was equivalent (P > 0.48) to bulk stool for all targets when 50 mul of F

188 time (P = 1.5 x 10-3), FPGS mRNA expression (P = 2.1 x 10-3), and MTX systemic clearance (P = 4.4 x 1

189 ated with the metabolic subtype (KCNH7/FIGN, P = 1.0 x 10-8).

190 HopO1-1 is required for P. syringae to spread locally to neighboring tissues dur

191 To date, a binding site for P on L had not been described.

192 onchodilator FEV(1) (P = 0.007), FEV(1)/FVC (P = 0.003), and greater computed tomography-based emphys

193 of glaucoma, including open-angle glaucoma (P = 0.36), chronic angle closure glaucoma (P = 0.85) and

194 (P = 0.36), chronic angle closure glaucoma (P = 0.85) and OHT (P = 0.42).

195 D >=4,000 mg/m(2) and radiotherapy <40 Gray (P = 0.012).

196 s (diet/exercise) than the usual care group (P < 0.05).

197 he active group and 36.4% in the sham group (P = 0.6).

198 e more common in both peppermint oil groups (P < .005).

199 DBG/HV when compared with the other groups (P <=0.05).

200 e of bipyridine, or using the excess of the >P(O)H reagent as the P-ligand.

201 HRs) were reviewed for individuals harboring P/LP variants who were predicted to develop disease (G+)

202 Compared with HDL-C, HDL-P was consistently associated with MI and ischemic strok

203 13.4+/-2.7 versus control, 11.7+/-1.7 mm Hg, P<0.0001).

204 hese results shed light on how mucus impacts P. aeruginosa behavior, and may inspire novel approaches

205 ed to wild-type monocytes (~3-fold increase; P < 0.05) led to reductions in cerebral soluble amyloid-

206 impaired 7% (IQR = 0-19) after indomethacin (P = 0.04), but not significantly associated with reducti

207 ess in GBM, particularly tumor infiltration (P = .0044) and hyperplastic blood vessels (P = .0005).

208 els, in comparison to DM+INS and DM+RSV+INS (P < 0.05).

209 ectively (age trend P < 0.05 and interaction P = 0.041).

210 ficance (PRDM2/KAZN, P = 2.2 x 10-10; IQCA1, P = 2.8 x 10-9; BMPR1B/UNC5C, P = 9.7 x 10-9; CDH10, P =

211 ype at genome-wide significance (PRDM2/KAZN, P = 2.2 x 10-10; IQCA1, P = 2.8 x 10-9; BMPR1B/UNC5C, P

212 hen resulted in enhanced occupancy of NF-kB, P-TEFb, and serine 2 phosphorylated RNA Polymerase II on

213 .019), C-reactive protein (198 vs. 107 mg/L, P = .010) and D-dimer (8.6 vs. 2.1 ug/mL, P = .004) leve

214 i, as associated with high expression level (P <= 0.001) of Peak # 15 (2 x Neu5Gc) compared to contro

215 was associated with higher TNF-alpha levels (P = .013).

216 ear mixed models, including biomarker [log10(P/B ratio) and/or AMY1 CN] diet-group interactions.

217 T and FAZ diameter were significantly lower (P < .05).

218 eins 3, GSDMB, or gasdermin A (3.1 x 10(-9) <P < 1.8 x 10(-4)).

219 tic fit between time per bite and bite mass (P = 0.006).

220 he accumulated dose of gadoterate meglumine (P=0.9064; rho=-0.0164 [95%]).

221 d comprises the analysis of 20 elements (Mg, P, S, K, Ca, V, Cr, Mn, Fe, Co, Cu, Zn, Se, Br, Rb, Sr,

222 n was 22% greater (+0.66 +/- 0.11 mg/kg/min, P < 0.05) than in subjects receiving placebo, and it was

223 CI): 266 (77, 455) nmol.min-1.kg-1.180 min; P = 0.01; eta2p = 0.44].

224 : 4266 (261, 8270) mumol.min-1.kg-1.180 min; P = 0.04; eta2p = 0.31] and branched-chain amino acids (

225 ups had decreases in HBsAg to below 1 IU/mL (P < .001 vs control) and HBsAg seroconversion (P = .046

226 L, P = .010) and D-dimer (8.6 vs. 2.1 ug/mL, P = .004) levels, and lower nadir lymphocyte counts (0.0

227 r than in the HMS group (27.6 vs. 17.0 mmHg, P < 0.001).

228 difference, 1.0 mmHg; 95% CI, 0.2-1.8 mmHg; P = 0.02).

229 ea on multiple linear mixed-effect modeling (P = .055); however, patient height and height squared we

230 Fungal N:P varied comparatively less due to simultaneous reductio

231 when compared to DM+RSV, DM+RSV+INS and NDM (P < 0.05).

232 penem/cilastatin/relebactam was noninferior (P < .001) to piperacillin/tazobactam for both endpoints:

233 hotography, fundus autofluorescence, or OCT (P = 0.35-0.99).

234 did not exceed 0.5 mm (82% of S and 100% of P below this value).

235 Compared to B-type (non-variant) cells of P. polymyxa strain E681, its phenotypic variant, termed

236 3) to the pleckstrin homology (PH) domain of P-Rex1 is required for its activation in cells.

237 r findings demonstrated the effectiveness of P-Tris affinity nanofiber membrane for the recovery of l

238 Circumsporozoite protein (CSP) variants of P. vivax, besides having variations in the protein repet

239 c angle closure glaucoma (P = 0.85) and OHT (P = 0.42).

240 l complications (6.6% EVR versus 38.0% open; P<0.001).

241 ] EVR versus $31 442 [$24 669-$40 419] open; P<0.001), driven by a lower rate of in-hospital complica

242 not statistically different from each other (P=0.50).

243 lower than predicted, while the particulate P (PP) load was similar to the predicted value.

244 mildly increase (3% bezafibrate, 5% placebo, P = .14).

245 er-operating curve of 5.4 percentage points (P <= 1.0 x 10(-9)).

246 tion compared with 25.0% postimplementation (P = .32).

247 n delivery did not differ between protocols (P > 0.05).

248 mpact on DeltaRNFL in the opposite quadrant (P > 0.05).

249 ce between dentate and edentulous quadrants (P < 0.001).

250 e SLC19A1/(ABCC1 + ABCC4) transporter ratio (P = 3.6 x 10-4), the MTX infusion time (P = 1.5 x 10-3),

251 y, we found that the 2019 dissolved reactive P (DRP) load from March-July was 29% lower than predicte

252 e had a statistically significant reduction (P < 0.05) in viral titer in liver and spleen at day 5 po

253 ignificantly increase the odds of rejection (P < .1).

254 ate-, and adverse-risk groups, respectively (P < .001).

255 .8 (5.0), and 9.5 (4.1) mm Hg, respectively (P < .001, Kruskal-Wallis test).

256 , 0.4 +/- 0.2 and 0.4 +/- 0.1, respectively; P < 0.01).

257 cytosis (31%, 47-80%, and 33%, respectively; P < 0.05-0.0001).

258 (49% [28/57] and 30% [16/53], respectively; P = .043; RR 1.63, 95% CI 1.0-2.65).

259 vs. 0.83 [95% CI, 0.69-0.93], respectively; P < 0.001).

260 31 cases/100 000 person-years, respectively; P < .001).

261 ar (1.3 vs. 2.1 vs. 1.6 years, respectively; P = 0.53).

262 (45+/-14 versus 49+/-16 years, respectively; P=0.04).

263 RNase P and MRP are highly conserved, multi-protein/RNA comple

264 orm alternative to the native fold for RNase P to bind and mature SRP RNA co-transcriptionally.

265 sociated with artifacts on the macular scan (P < .001).

266 , 0.3) to 2.8 (SD, 0.2) on the EDTSES score (P = 0.007).

267 therapy improved patients' HRCT scan scores (P < .0001), forced vital capacity (P = .0017), FEV(1) (P

268 < .001 vs control) and HBsAg seroconversion (P = .046 vs control).

269 No significant (P < .01) covariates remained after backward elimination

270 en the 2 treatment arms was not significant (P = .09).

271 offs resulting in statistically significant (P < 0.005) differences between benign and malignant lesi

272 roblems) remained statistically significant (P < 0.01).

273 ltivariable model including the ALL subtype (P = 1.1 x 10-14), the SLC19A1/(ABCC1 + ABCC4) transporte

274 0-2] in patients with any positive BDG test; P = .039).

275 Among the P. aeruginosa isolates, 2 (6.9%) VMEs and 3 (3.3%) MEs w

276 sing the excess of the >P(O)H reagent as the P-ligand.

277 We hypothesize that one function of the P and L rings is to seal the outer membrane after motor

278 increased with dosage (P = 0.013) and time (P < 0.001) in Study 1 and with time in Study 2 (P < 0.00

279 tio (P = 3.6 x 10-4), the MTX infusion time (P = 1.5 x 10-3), FPGS mRNA expression (P = 2.1 x 10-3),

280 .9% (95% CI, 17.7%-20.2%), stable over time (P > .05 for both 2010-2016 and 2003-2009 vs 1996-2002),

281 ons and bleeding events decreased over time (P value for trend test <0.0001); however, there was sign

282 own TMIE versus 12.4% after Ivor Lewis TMIE (P = 0.003).

283 cutive generations of animals are exposed to P. vranovensis.

284 nd Latino Americans, respectively (age trend P < 0.05 and interaction P = 0.041).

285 psia/eclampsia or be in the third trimester (P <= 0.01).

286 lymphocyte counts (0.09 vs. 0.4 x 10(3) /uL, P = .006).

287 te blood cell counts (15.8 vs 7 x 10(3) /uL, P = .019), C-reactive protein (198 vs. 107 mg/L, P = .01

288 10-10; IQCA1, P = 2.8 x 10-9; BMPR1B/UNC5C, P = 9.7 x 10-9; CDH10, P = 1.2 x 10-8) and one locus tha

289 ypotheses of plant responses to eCO(2) under P limitation, thereby improving projections of future gl

290 s yielding statistically significant values (P < .001).

291 (P = .0044) and hyperplastic blood vessels (P = .0005).

292 th increased number of postoperative visits (P-value < 0.05).

293 There was a significantly higher WCC(P=0.014) and CRP(P=0.004) on admission in P2.

294 antly associated with 90-day mortality were: P: age, gender and ACLF type; I: drug, infection, surger

295 metagenome sequence data is significant with P-values less than 4.04E-17.

296 the basalt treatment after 120 days without P- and K-fertilizer addition.

297 Yao P, Bennett D, Mafham M, et al.

298 ning in uninjected eyes was -0.620 mum/year (P = .029).

299 patients at <5 years to 3.8% at >=10 years, P=0.02).

300 ments were statistically equivalent to zero (P < 0.04).